Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Andrew M Evens, DO, MSc
University of Massachusetts, Worcester
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Alta Bates Summit Medical Center-Herrick
Berkeley, California, United States
- Providence Saint Joseph Medical Center
Burbank, California, United States
- Halifax Health- Center for Oncology
Daytona Beach, Florida, United States
- Rush University Medical Center
Chicago, Illinois, United States
- Loyola University Chicago
Maywood, Illinois, United States
- Oncology Specialists
Park Ridge, Illinois, United States
- University of Massachusetts - Worcester
Worcester, Massachusetts, United States
- Hackensack Medical Center
Hackensack, New Jersey, United States
- West Virginia University, Wvu Healthcare
Morgantown, West Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2011
- Primary completion
- 30 Jun 2014
- Completion
- 31 May 2015
- Last update posted
- 4 Oct 2021
- Registered enrollment
- 5
- Registry id
- NCT01549886
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.